The 12-month open-label trial for the RD program may not be necessary for filing, but it will provide valuable insights. The XPro trial results will be communicated staggered, focusing on cognitive and functional evidence. FDA's stance on EMAC is awaited.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing